Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Gross Profit | -8.1M | 6.4% |
| Cost of Revenue | 7.6M | 11.8% |
| Operating expense | 20M | 25.1% |
| Net Income | -19M | 23% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 113M | 5.7% |
| Total Liabilities | 45M | 33.3% |
| Total Equity | 69M | 6.8% |
| Shares Outstanding | 36M | 38.6% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -20M | 28.3% |
| Cash from investing | 35M | 146.1% |
| Cash from financing | 29M | 4311.6% |
EPS
Financial Highlights for Inovio Pharmaceuticals in Q4 '24
Gross Profit stood at -8.1M, marking a 6.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 7.6M, a -11.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 20M, showing a -25.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -19M, showing a 23% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
